WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314217
Description: Deferiprone is a drug that chelates iron and is used to treat thalassaemia major. In 1994 was first approved for use in treating thalassaemia major in 1994 and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States. On October 14, 2011, it was approved for use in the US under the FDAÂ’s accelerated approval program.
MedKoo Cat#: 314217
Chemical Formula: C7H9NO2
Exact Mass: 139.06333
Molecular Weight: 139.15
Elemental Analysis: C, 60.42; H, 6.52; N, 10.07; O, 23.00
Deferiprone, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
IUPAC/Chemical Name: 3-hydroxy-1,2-dimethylpyridin-4(1H)-one
InChi Key: TZXKOCQBRNJULO-UHFFFAOYSA-N
InChi Code: InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3
SMILES Code: O=C1C(O)=C(C)N(C)C=C1
The following data is based on the product molecular weight 139.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2013 Aug 21;8:CD004839. doi: 10.1002/14651858.CD004839.pub3. Review. PubMed PMID: 23966105.
2: Pandolfo M, Hausmann L. Deferiprone for the treatment of Friedreich's ataxia. J Neurochem. 2013 Aug;126 Suppl 1:142-6. doi: 10.1111/jnc.12300. Review. PubMed PMID: 23859349.
3: Deferiprone (Ferriprox) for iron overload. Med Lett Drugs Ther. 2012 Feb 20;54(1384):15-6. Review. PubMed PMID: 22354281.
4: Pontikoglou C, Papadaki HA. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. Hemoglobin. 2010 Jun;34(3):291-304. doi: 10.3109/03630269.2010.484791. Review. PubMed PMID: 20524819.
5: Cappellini MD, Musallam KM, Taher AT. Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin. 2009;33 Suppl 1:S58-69. doi: 10.3109/03630260903346924. Review. PubMed PMID: 20001633.
6: Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci (Elite Ed). 2009 Jun 1;1:161-78. Review. PubMed PMID: 19482634.
7: Vlachaki E, Tselios K, Perifanis V, Tsatra I, Tsayas I. Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature. Clin Rheumatol. 2008 Nov;27(11):1459-61. doi: 10.1007/s10067-008-0969-y. Epub 2008 Jul 29. Review. PubMed PMID: 18663554.
8: Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin. 2008;32(1-2):1-15. doi: 10.1080/03630260701726533. Review. PubMed PMID: 18274978.